Biomarkers for predicting immunotherapy response and resistance in glioblastoma - Takeaways - MDSpire

Biomarkers for predicting immunotherapy response and resistance in glioblastoma

  • By

  • Samuel Kim

  • Matthew Abikenari

  • Brandon Bergsneider

  • Lily H. Kim

  • Michael Lim

  • May 5, 2026

  • 0 min

Share

  • 1

    Glioblastoma is the most aggressive primary brain tumor in adults, with a median survival of only 12–18 months despite current treatments.

  • 2

    Biomarkers are critical for identifying glioblastoma patients who may respond to immunotherapy and for informing treatment combinations.

  • 3

    Current single biomarkers for predicting immunotherapy response in glioblastoma have shown inconsistent results across studies.

  • 4

    New context-dependent biomarkers, including immune cell studies and radiographic signals, show promise for improving treatment outcomes.

  • 5

    Standardizing biomarkers in glioblastoma immunotherapy requires early implementation and uniformity in clinical trial endpoints.

Original Source(s)

Biomarkers for predicting immunotherapy response and resistance in glioblastoma

  • by Samuel Kim, Matthew Abikenari, Brandon Bergsneider, Lily H. Kim, Michael Lim

  • May 5, 2026

Related Content

Editorial: Overcoming resistance to immune checkpoint inhibitors: mechanisms and strategies in cancer therapy

Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumors

A case of synchronous double primary combined hepatocellular-cholangiocarcinoma complicated with gallbladder adenocarcinoma: a rare case report